Latest news and press releases about IceCure Medical Ltd (ICCM): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
Price
| Price | $2.06 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| Price / Book | 0.53 |
| EV / EBITDA | 0.42 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -174.26% |
| Return on Invested Capital | -183.21% |
| Return on Assets | -95.33% |
| Gross Margin | 36.10% |
| Operating Margin | -556.35% |
| Net Margin | -427.67% |
Related companies: BDMD · CTSO · ECOR · MDAI · MDCX · PETS · SRTS
Explore sector: Healthcare · Medical - Devices
More sections of ICCM: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks